Skip to main content
Let's spread the word about Immunotherapy! Click to share this page with your community.

Immuno-Oncology 360°: Connecting Science & Business to Advance Immunotherapy

December 19, 2016

During the first three days of February, The Roosevelt Hotel in New York City will host the 3rd annual Immuno-Oncology 360° (IO360°) conference, which will bring together experts from all areas of immuno-oncology and cancer immunotherapy, from preclinical and clinical advancements to business development.

The event is being hosted by the Conference Forum, and was designed by Dr. Axel Hoos―a member of CRI’s Scientific Advisory Council, co-chairman of the CRI Cancer Immunotherapy Consortium (CIC) Steering Committee, and vice president for oncology research and development at GlaxoSmithKline―and Dr. James Gulley of the National Cancer Institute.

As the name IO360° indicates, the meeting aims to be “comprehensive, and provide direction and feedback for all stakeholders,” notes Hoos. With sessions covering preclinical science, translational science and new technologies, trends and collaborations in the IO space, business aspects of immuno-oncology, and clinical advancements, Hoos envisions “something in the conference for everyone in that space.”

He’s particularly excited about the session on trends and collaborations, which will focus on the importance of new organizations, partnerships, and initiatives in the cancer immunotherapy field. During this session, Dr. Jill O’Donnell-Tormey, CRI’s chief executive officer and director of scientific affairs, will be speaking as well as serving as a panel member alongside Dr. Daniel Chen, who co-chairs CRI’s CIC Steering Committee with Dr. Hoos and is the cancer immunotherapy franchise head in product development at Genentech.

Dr. James P. Allison, director of CRI’s Scientific Advisory Council and chair of the Immunology Department at MD Anderson Cancer Center, will be giving the keynote speech. Other notable speakers include Johns Hopkins’ Dr. Charles Drake, who will be speaking during the preclinical science session, and MD Anderson Cancer Center’s Dr. Patrick Hwu, who will be presenting in the first clinical advancements session. Drake and Hwu are both also members of CRI’s Scientific Advisory Council.

Learn more about the 2017 conference’s agenda and register today using discount code CRI20 to receive 20% off the registration fee.

Be in the know with the latest immunotherapy news

*Immunotherapy results may vary from patient to patient.

Top